European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals

First Page		Document Content
Medicine Clinical medicine Cancer Tyrosine kinase receptors Breast cancer Atezolizumab ROS1 Triple-negative breast cancer Anaplastic lymphoma kinase Trastuzumab emtansine Entrectinib Metastatic breast cancer		European Society for Medical Oncology (ESMOCongress Roche Analyst Audio Webcast Monday, 22 October 2018 Welcome Daniel O’Day, CEO Roche Pharmaceuticals Add to Reading List Source URL: www.roche.com Download Document from Source Website File Size: 2,40 MB Share Document on Facebook

	EDITORIAL STAFF From the Editor Debu Tripathy, MD Editor-in-Chief DocID: 1oyvT - View Document
	Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 217 Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2Breast Cancer DocID: 1mOZw - View Document
	Kadcyla, INN-trastuzumab emtansine DocID: 15dBb - View Document
	Perez et al. Breast Cancer Research 2014, 16:R50 http://breast-cancer-research.com/content/16/3/R50 RESEARCH ARTICLE Open Access DocID: 11w2y - View Document
	Barok et al. Breast Cancer Research 2014, 16:209 http://breast-cancer-research.com/contentREVIEW Trastuzumab emtansine: mechanisms of action DocID: 11uMA - View Document